Affiliations 

  • 1 Department of Neurology, Minaminara General Medical Center, Yoshino, Nara, Japan
  • 2 Department of Infection, Minaminara General Medical Center, Yoshino, Nara, Japan
  • 3 Department of Biomedical Engineering, Faculty of Engineering, University of Malaya, Kuala Lumpur, Malaysia
  • 4 Department of Human Genetics and Molecular Biology, Bharathiar University, Coimbatore, Tamil Nadu, India
  • 5 Department of Neurology, Nara Medical University School of Medicine, Kashihara, Nara, Japan
  • 6 Department of Neurology, Nara Medical University School of Medicine, Kashihara, Nara, Japan. [email protected]
Neuroradiology, 2022 Oct;64(10):2085-2089.
PMID: 35809100 DOI: 10.1007/s00234-022-03010-y

Abstract

A 23-year-old previously healthy man (Patient 1) and a 33-year-old woman with a past history of depression (Patient 2) developed neurological symptoms approximately 1 week after receipt of the first COVID-19 mRNA vaccination and deteriorated over the next week. Patient 1 reported nausea, headache, a high fever, and retrograde amnesia. Patient 2 reported visual disturbance, headache, dysarthria, a left forearm tremor, dysesthesia of the mouth and distal limbs, and visual agnosia. PCR test results for SARS-CoV-2 were negative. Complete blood cell count, biochemistry, and antibody test and cerebrospinal fluid test findings were unremarkable. Diffusion-weighted and fluid-attenuated inversion recovery MRI of the brain showed a high signal intensity lesion at the midline of the splenium of the corpus callosum compatible with cytotoxic lesions of the corpus callosum (CLOCCs). High-dose intravenous methylprednisolone improved their symptoms and imaging findings. CLOCCs should be considered in patients with neurological manifestation after COVID-19 vaccination.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.